25 drugs reach their earliest generic-entry date in 2044

Jan 2044 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Inzirqo hydrochlorothiazide	hydrochlorothiazide	Novitium Pharma	219141	23 Jan 2044	patent
Omcazio · 3 strengths cabozantinib laurylsulfate	cabozantinib laurylsulfate	Handa Oncol	220613	30 Jan 2044	patent

Feb 2044 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Artesunate artesunate	artesunate	Amivas	213036	16 Feb 2044	patent

Mar 2044 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Iqirvo elafibranor	elafibranor	Ipsen	218860	5 Mar 2044	patent
Vizz aceclidine hydrochloride	aceclidine hydrochloride	Lenz Therap	218585	15 Mar 2044	patent, carve-out possible
Palsonify · 2 strengths paltusotine hydrochloride	paltusotine hydrochloride	Crinetics	219070	25 Mar 2044	patent, carve-out possible

Apr 2044 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Desmoda desmopressin acetate	desmopressin acetate	Eton	219873	3 Apr 2044	patent

May 2044 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Bysanti · 7 strengths milsaperidone	milsaperidone	Vanda Pharms Inc	220358	31 May 2044	patent, carve-out possible

Jun 2044 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Ohtuvayre ensifentrine	ensifentrine	Msd	217389	25 Jun 2044	patent

Jul 2044 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Exparel · 2 strengths bupivacaine	bupivacaine	Pacira Pharms Inc	022496	2 Jul 2044	patent
Komzifti ziftomenib	ziftomenib	Kura	220305	16 Jul 2044	patent
Aurlumyn iloprost	iloprost	Btg Intl	217933	18 Jul 2044	patent, carve-out possible
Zusduri mitomycin	mitomycin	Urogen Pharma	215793	25 Jul 2044	patent, carve-out possible

Aug 2044 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Suflave magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate	magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate	Azurity	215344	2 Aug 2044	patent
Phenylephrine Hydrochloride In 0.9% Sodium Chloride phenylephrine hydrochloride	phenylephrine hydrochloride	Dr Reddys Labs Sa	216830	8 Aug 2044	patent

Sep 2044 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Tirosint · 15 strengths levothyroxine sodium	levothyroxine sodium	Ibsa	021924	26 Sep 2044	patent
Tirosint-Sol · 15 strengths levothyroxine sodium	levothyroxine sodium	Ibsa	206977	26 Sep 2044	patent
Vasopressin In Sodium Chloride 0.9% · 2 strengths vasopressin	vasopressin	Baxter Hlthcare Corp	217569	27 Sep 2044	patent

Oct 2044 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Atmeksi methocarbamol	methocarbamol	Rosemont Pharms	219843	9 Oct 2044	patent
Gomekli · 2 strengths mirdametinib	mirdametinib	Springworks	219389	10 Oct 2044	patent, carve-out possible
Gomekli · 3 strengths mirdametinib	mirdametinib	Springworks	219379	10 Oct 2044	patent, carve-out possible
Leqselvi deuruxolitinib phosphate	deuruxolitinib phosphate	Sun Pharm Inds Inc	217900	10 Oct 2044	patent, carve-out possible

Nov 2044 · 1

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Ryaltris mometasone furoate; olopatadine hydrochloride	mometasone furoate; olopatadine hydrochloride	Glenmark Speclt	211746	21 Nov 2044	patent

Dec 2044 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Vykoura · 3 strengths leucovorin calcium	leucovorin calcium	Avyxa Holdings	220406	23 Dec 2044	patent
Ponvory · 2 strengths ponesimod	ponesimod	Vanda Pharms Inc	213498	24 Dec 2044	patent, carve-out possible